Conversely, therapeutic inhibition of NaCT in the liver is a target to improve metabolic diseases, including non-alcoholic fatty liver disease, obesity, and insulin resistance. Here, SLC13A2 is linked to metabolic dysfunction-associated steatotic liver disease.